and Human Services (HHS)
EXPIRED
CORRELATIVE STUDIES USING SPECIMENS FROM MULTI-INSTITUTIONAL PREVENTION AND
TREATMENT TRIALS
Release Date: November 13, 2000 (see replacement PA-03-064)
PA NUMBER: PA-01-015
National Cancer Institute
Letter of Intent Date: Jan. 4, 2001, May 4, 2001, Sep. 3, 2001,
Jan. 4, 2002, May 3, 2002, Sep. 3, 2002
Receipt Date: Regular receipt dates
THIS PA USES THE "MODULAR GRANT" AND "JUST-IN-TIME" CONCEPTS. IT INCLUDES
DETAILED MODIFICATIONS TO STANDARD APPLICATION INSTRUCTIONS THAT MUST BE USED
WHEN PREPARING APPLICATIONS IN RESPONSE TO THIS PA.
This Program Announcement (PA) replaces PA-98-099, which was published in NIH
Guide, August 14, 1999.
This PA will expire on October 2, 2002.
PURPOSE
The Cancer Therapy Evaluation Program and the Cancer Diagnosis Program of the
Division of Cancer Treatment and Diagnosis and the Cancer Biomarkers Research
Group of the Division of Cancer Prevention, National Cancer Institute invite
research grant applications from institutions or consortia capable of
performing clinical translational research on promising predictive and
prognostic markers. These studies should focus on clinical correlative or
mechanistic studies that will be useful for cancer risk assessment, early
detection, prognosis, and for predicting response to therapy and to prevention
interventions. NCI encourages accessing tissue specimens from the NCI
Clinical Trials Cooperative Groups (NCI Cooperative Groups) or other large
multi-institutional treatment and prevention clinical trials that have studied
well defined patient populations and have outcome data available. This
Program Announcement (PA) is intended to support collaborations between
researchers with promising correlative markers and clinical trials groups with
access to patient populations essential for validation studies. Researchers
who are interested in accessing specimens are encouraged to contact the NCI
Cooperative Groups or visit the Cancer Diagnosis Program website
(http://www.specimens.ims.nci.nih.gov) if ongoing collaborations are not in
place.
This PA will utilize the investigator-initiated research project grant (R01)
mechanism for analysis of specimens from large multi-institutional clinical
trials and the exploratory/pilot grant (R21) mechanism for pilot exploratory
studies.
Investigators interested in conducting laboratory correlative studies on
single institution trials may also consider two additional Program
Announcements from the National Cancer Institute: PA-01-010 (Exploratory
Studies in Detection, Diagnosis, and Prediction) and PA-00-047 (Quick-Trials
for Novel Cancer Therapies). Exploratory studies focused on cancer imaging,
including new imaging modalities, agents and analysis methods, are more
appropriate for PA-98-008 (Exploratory/Developmental Grants for Diagnostic
Cancer Imaging), sponsored by the NCI Biomedical Imaging Program.
RESEARCH OBJECTIVES
Background
The NCI supports an extensive network of clinical and laboratory research
studies related to cancer detection, prevention and therapy through contracts,
grants and cooperative agreements. The Cancer Therapy Evaluation Program
(CTEP), Division of Cancer Treatment and Diagnosis (DCTD) supports a program
of integrated national networks of clinical investigators and institutions
(NCI Clinical Trials Cooperative Groups) for the conduct of large scale,
multi-institutional clinical trials. The Community Oncology and Prevention
Trials Research Group, Division of Cancer Prevention (DCP), supports programs
to improve clinical oncology in community settings and conduct prevention and
control trials. Presently, the NCI Cooperative Groups conduct approximately
400 clinical trials evaluating approximately 20,000 cancer patients per year.
The Cooperative Groups have established tumor banks that provide access to
tumor specimens from large numbers of patients with a variety of malignancies.
The clinical trials organizations maintain statistical databases and are
capable of correlating laboratory data with clinical outcome. The Early
Detection Research Network (EDRN) of the Division of Cancer Prevention has
created a research platform for collaborating with the clinical trials
community and appointed liaisons for the various NCI Cooperative Groups. The
EDRN is available for assistance in validation studies and researchers may
form collaborations through its Associate Member Program
(http://edrn.nci.nih.gov).
Recently, investigators in molecular genetics and immunobiology have
discovered new promising biomarkers that may identify patients who would
benefit from specific therapeutic strategies. Technological advances in PCR,
flow cytometry, immunohistochemistry, in situ hybridization and high-
throughput, high yield array technologies will allow laboratory investigators
to do multiple analyses on tumor specimens and study tumor heterogeneity in a
variety of tumor types. Many opportunities exist for conducting correlative
laboratory studies that may be immediately relevant to cancer treatment. In
addition, opportunities exist for the molecular characterization of precancer
and early stage cancer through analysis of specimens from treatment and
prevention trials.
This PA is designed to promote collaborations and interactions between basic
researchers and clinical investigators to advance research on clinical
correlations that can improve therapeutic approaches. NCI is seeking to
encourage correlative laboratory studies linked to large scale multi-
institutional clinical trials. In many instances, the laboratory
investigators are already recipients of R01 or P01 support for their basic
research. These laboratory investigators may not have access to patient
specimens or outcome data for large scale analysis. The Clinical Trials
Cooperative Groups have established tumor and specimen banks for specific
diseases, and reference labs necessary for the diagnosis and monitoring of
patients. This initiative proposes to link these peer-approved activities and
for a relatively small additional investment provide a mechanism to obtain
definitive data on the relationship of biological features and the clinical
behavior of the tumors or other human tissues. Objectives and approaches will
be investigator-initiated with NCI assisting investigators to assure that
promising new approaches will be moved rapidly into clinical practice.
Research Goals and Scope
The objectives of this PA are to foster collaborations and interactions
between basic researchers, private industry, and clinical investigators to
perform clinical translational research on promising predictive and prognostic
markers. These studies should focus on clinical correlative or mechanistic
studies that will be useful for cancer risk assessment, early detection,
prognosis, and predicting response to therapy and to prevention interventions.
These studies should focus on correlations between biologic features of tissue
specimens collected from the NCI Cooperative Groups or other large
multi-institutional clinical trials and patient outcomes.
This PA will utilize the R01 investigator initiated research grant mechanism
to support clinical correlative studies on large multi-institutional clinical
trials for validation of promising predictive or prognostic markers and the
exploratory/pilot grant mechanisms (R21) to support pilot exploratory
studies. For the R01 grant submissions, preliminary data, including relevant
animal models or analysis of patient specimens, that supports the hypotheses
must be provided. Because the R21 grant mechanism is designed to support
pilot or feasibility studies, preliminary data as evidence of feasibility are
not required. The correlative studies should be based on strong and testable
hypotheses. A clear rationale should be given for the experimental design and
technical methodologies selected. The hypotheses tested must relate to
potential clinical applications such as patient monitoring for preventive or
therapeutic interventions, development of new therapeutic strategies or
testing new biomarkers for the identification of patient subsets for specific
prevention or treatment approaches. The laboratory assays must use specimens
from patients receiving defined treatments in large clinical trials such as
phase III clinical trials. Applications must include a statistical section
describing the study design and plans for analysis of data designed to test
the hypotheses. All investigators are encouraged to work with
multi-institutional organizations or form a consortium in order to access
sufficient numbers of patient specimens and clinical information to test the
proposed hypotheses.
Some examples of therapeutic laboratory correlates may include but are not
limited to: (1) phenotypic or genotypic alterations which appear to correlate
with the development of therapy resistance; (2) loss or inactivation of tumor
suppressor genes related to prognosis; (3) analysis of basal membrane factors
or genes related to tumor invasion and metastases; (4) studies of chromosomal
rearrangements or deletions that may be used for risk assessment, early
detection, or prognosis; (5) correlation of tumor growth factors or oncogenes
with response to therapies during cancer progression; (6) alterations in cell
cycle control; (6) characterization of immune response with association to new
immunotherapies for prevention or treatment; (7) evaluation of serum or tumor
biomarkers for risk assessment, early detection, or prognosis; (8) analyses of
expression of cellular receptors for growth factors or differentiating agents;
(9) defining and targeting specific populations of cells for therapy; (10)
analysis of in vitro response of tumor cells to growth factors/differentiating
agents; and (11) evaluating accessible sites for precancerous changes
occurring in less accessible sites, for instance the oral cavity as a
surrogate site for the lung in smokers. Surrogate sites may be anatomically-
associated, such as oral cavity to lung cancer, or may be functionally
related, such as scalp hair follicles to prostate cancer, both of which have
androgen receptors.
Researchers who have previously not collaborated with the NCI Cooperative
Groups or Division of Cancer Prevention Programs are encouraged to contact
them and discuss potential collaborations to obtain access to NCI-supported
specimen banks and outcome data for laboratory analysis under this PA. NCI
staff (see Inquiries) will be able to provide assistance in identifying NCI
Cooperative Groups that would be interested in collaborating with basic
science investigators on laboratory and clinical studies of new markers. The
NCI Tissue Expediter is available to assist investigators in determining the
appropriate tissue resource for their research project
(http://www.cdp.ims.nci.nih.gov/expediter.html). Information on how to access
NCI-supported specimen banks including contacts for the NCI Cooperative Group
banks is available at the following web address:
http://www.specimens.ims.nci.nih.gov. The NCI Cooperative Groups have
mechanisms in place to review proposals for access to NCI Cooperative Group
tissue banks from prevention and treatment trials. A letter from the
appropriate NCI Group Chair confirming approval to provide specimens in the
event of NCI funding of the PA grant application should be included in the
grant application. For Intergroup tissue banks, a letter from the Intergroup
tissue bank chair should also be included.
MECHANISM OF SUPPORT
Support of this program will be through the National Institutes of Health
(NIH) research project grant (R01) mechanism and the exploratory/developmental
grant (R21) mechanism. Applicants will be responsible for the planning,
direction, and execution of the proposed project. All PHS and NIH grants
policies will apply to applications received and awards made in response to
this PA. Applicants for the R21 grant mechanism may request up to $100,000
direct costs (four budget modules) per year unless the application includes
consortium costs, in which case the limit is $125,000 direct costs (five
budget modules) per year and support may not exceed two years. The R21 grants
are non-renewable and competitive continuation of projects developed under
this program will be through the R01 research grant mechanism. Applications
for the R01 grant mechanism may not exceed five years. NIH grants policies
apply to these awards.
Future unsolicited competing continuation applications will compete with all
investigator-initiated applications and be reviewed according to the customary
peer review procedures.
Specific application instructions have been modified to reflect "MODULAR
GRANT" and "JUST-IN-TIME" streamlining efforts being examined by the NIH.
Complete and detailed instructions and information on Modular Grant
applications can be found at
http://grants.nih.gov/grants/funding/modular/modular.htm.
ELIGIBILITY REQUIREMENTS
Applications may be submitted by foreign and domestic, for-profit and
non-profit organizations, public and private, such as universities, colleges,
hospitals, laboratories, units of State and local governments, and eligible
agencies of the Federal government. Applications may be from a single
institution or may include arrangements with one or more institutions (e.g.,
consortia, NCI Groups) if appropriate. Racial/ethnic minority individuals,
women, and persons with disabilities are encouraged to apply as Principal
Investigators.
INQUIRIES
Inquiries are encouraged. The opportunity to clarify any issues or questions
from potential applicants is welcome.
Direct inquiries regarding programmatic issues to:
Ms. Diane Bronzert
Cancer Therapy Evaluation Program
National Cancer Institute
6130 Executive Boulevard, Room 734, MSC 7432
Bethesda, MD 20892-7432
Telephone: (301) 496-8866
FAX: (301) 480-4663
Email: [email protected]
Dr. Tracy Lugo
Cancer Diagnosis Program
National Cancer Institute
6130 Executive Boulevard, Room 6035A, MSC 7388
Bethesda, MD 20892-7388
Telephone: (301) 496-1591
FAX: (301) 402-7819
Email: [email protected]
Dr. Donald Henson
Division of Cancer Prevention
National Cancer Institute
6130 Executive Boulevard, Room 305
Bethesda, MD 20892
Telephone: (301) 496-9424
FAX: (301) 496-8667
Email: [email protected]
Direct inquiries regarding NCI supported specimen banks to:
Ms. Marianna Bledsoe
Cancer Diagnosis Program
National Cancer Institute
6130 Executive Boulevard, Room 6035A, MSC 7388
Bethesda, MD 20892-7388
Telephone: (301) 496-7147
FAX: (301) 402-7819
Email: [email protected]
Direct inquiries regarding fiscal matters to:
Ms. Sara Stone
Grants Administration Branch
National Cancer Institute
6120 Executive Boulevard, Room 243, MSC 7150
Bethesda, MD 20892-7150
Telephone: (301) 496-9927
FAX: (301) 496-8601
Email: [email protected]
LETTER OF INTENT
Prospective applicants are asked to submit, a letter of intent by the dates
mentioned on the first page of this PA, that includes a descriptive title of
the proposed research, the name, address, and telephone number of the
Principal Investigator, the identities of other key personnel and
participating institutions (including NCI Groups or other tissue banks), and
the number and title of the PA in response to which the application may be
submitted.
Although a letter of intent is not required, is not binding, and does not
enter into the review of subsequent applications, the information is helpful
in planning for the review of applications. It allows staff to estimate the
potential review workload and plan the review.
The letter of intent is to be sent to Ms. Diane Bronzert listed under INQURIES
by the letter of intent receipt date.
APPLICATION PROCEDURES
The modular grant concept establishes specific modules in which direct costs
may be requested as well as a maximum level for requested budgets. Only
limited budgetary information is required under this approach. The
just-in-time concept allows applicants to submit certain information only when
there is a possibility for an award. It is anticipated that these changes will
reduce the administrative burden for the applicants, reviewers and Institute
staff. The research grant application form PHS 398 (rev. 4/98) is to be used
in applying for these grants, with the modifications noted below. Applications
will be accepted at the standard application deadlines as indicated in the
application kit. Applications kits are available at most institutional offices
of sponsored research and may be obtained from the Division of Extramural
Outreach and Information Resources, National Institutes of Health, 6701
Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone 301/710-0267,
email: [email protected]. The title and number of the PA must be typed on
line 2 of the face page of the application form and the YES box must be
marked. For those applicants with internet access, the 398 kit may be found
at: http://grants.nih.gov/grants/funding/phs398/phs398.html.
Applicants are encouraged to call the program contacts listed in INQUIRIES
above with any questions regarding the goals of this PA.
All clinical trials supported or performed by NCI require some form of
monitoring. The method and degree of monitoring should be commensurate with
the degree of risk involved in participation and the size and complexity of
the clinical trial. Monitoring exists on a continuum from monitoring by the
principal investigator/project manager or NCI program staff to a data and
safety monitoring board (DSMB). These monitoring activities are distinct from
the requirement for study review and approval by an Institutional Review Board
(IRB). For details about the Policy of the NCI for Data Safety Monitoring of
Clinical Trials see http://deainfo.nci.nih.gov/grantspolicies/datasafety.htm.
For phase I and II clinical trials, investigators must submit a general
description of the data and safety monitoring plan as part of the research
application. See NIH Guide Notice on Further Guidance on a Data and Safety
Monitoring for Phase I and II Trials for additional information:
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-038.html
SPECIFIC INSTRUCTIONS FOR MODULAR GRANT APPLICATIONS
BUDGET INSTRUCTIONS
Modular Grant applications will request direct costs in $25,000 modules, up to
a total direct cost request of $250,000 per year for R01 and, up to a total
direct cost request of $100,000 per year for R21. (Applications that request
more than $250,000 direct costs for R01 in any year must follow the
traditional PHS 398 application instructions.) The total direct costs must be
requested in accordance with the program guidelines and the modifications made
to the standard PHS 398 application instructions described below:
o FACE PAGE: Items 7a and 7b should be completed, indicating Direct Costs
(in $25,000 increments) and Total Costs [Modular Total Direct plus Facilities
and Administrative (F&A) costs] for the initial budget period. Items 8a and
8b should be completed indicating the Direct and Total Costs for the entire
proposed period of support.
o DETAILED BUDGET FOR THE INITIAL BUDGET PERIOD - Do not complete Form Page 4
of the PHS 398. It is not required and will not be accepted with the
application.
o BUDGET FOR THE ENTIRE PROPOSED PERIOD OF SUPPORT - Do not complete the
categorical budget table on Form Page 5 of the PHS 398. It is not required
and will not be accepted with the application.
o NARRATIVE BUDGET JUSTIFICATION - Prepare a Modular Grant Budget Narrative
page (see http://grants.nih.gov/grants/funding/modular/modular.htm for sample
pages). At the top of the page, enter the total direct costs requested for
each year. This is not a form page.
o Under Personnel, list all project personnel, including their names, percent
of effort, and roles on the project. No individual salary information should
be provided. However, the applicant should use the NIH appropriation language
salary cap and the NIH policy for graduate student compensation in developing
the budget request.
For Consortium/Contractual costs, provide an estimate of total costs (direct
plus facilities and administrative) for each year, each rounded to the nearest
$1,000. List the individuals/organizations with whom consortium or contractual
arrangements have been made, the percent effort of all personnel, and the role
on the project. Indicate whether the collaborating institution is domestic or
foreign. The total cost for a consortium/contractual arrangement is included
in the overall requested modular direct cost amount. Include the Letter of
Intent to establish a consortium.
Provide an additional narrative budget justification for any variation in the
number of modules requested.
o BIOGRAPHICAL SKETCH - The Biographical Sketch provides information used by
reviewers in the assessment of each individual's qualifications for a specific
role in the proposed project, as well as to evaluate the overall
qualifications of the research team. A biographical sketch is required for
all key personnel, following the instructions below. No more than three pages
may be used for each person. A sample biographical sketch may be viewed at:
http://grants.nih.gov/grants/funding/modular/modular.htm.
- Complete the educational block at the top of the form page;
- List position(s) and any honors;
- Provide information, including overall goals and responsibilities, on
research projects ongoing or completed during the last three years;
- List selected peer-reviewed publications, with full citations.
o CHECKLIST - This page should be completed and submitted with the
application. If the F&A rate agreement has been established, indicate the type
of agreement and the date. All appropriate exclusions must be applied in the
calculation of the F&A costs for the initial budget period and all future
budget years.
The applicant should provide the name and phone number of the individual to
contact concerning fiscal and administrative issues if additional information
is necessary following the initial review.
Submit a signed, typewritten original of the application, including the
checklist, and five signed, exact, single-sided photocopies, in one package
to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040 - MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
Applications must be received by the regular receipt dates indicated in the
application kit beginning February 1, 2001. The Center for Scientific Review
(CSR) will not accept any application in response to this PA that is
essentially the same as one currently pending initial review, unless the
applicant withdraws the pending application. The CSR will not accept any
application that is essentially the same as one already reviewed. This does
not preclude the submission of substantial revisions of applications already
reviewed, but such applications must include an introduction addressing the
previous critique.
REVIEW CONSIDERATIONS
Applications will be assigned on the basis of established Public Health
Service referral guidelines. Applications will be evaluated for scientific
and technical merit in accordance with the standard NIH peer review
procedures. As part of the initial merit review, all applications will
receive a written critique and undergo a process in which only those
applications deemed to have the highest scientific merit, generally the top
half of applications under review, will be discussed, assigned a priority
score, and receive a second level review by the appropriate national advisory
council or board.
Review Criteria
The five criteria to be used in the evaluation of grant applications are
listed below.
The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health. The
reviewers will comment on the following aspects of the application in their
written critiques in order to judge the likelihood that the proposed research
will have a substantial impact on the pursuit of these goals. Each of these
criteria will be addressed and considered by the reviewers in assigning the
overall score weighting them as appropriate for each application. Note that
the application does not need to be strong in all categories to be judged
likely to have a major scientific impact and thus deserve a high priority
score. For example, an investigator may propose to carry out important work
that by its nature is not innovative but is essential to move a field forward.
1. Significance. Does this study address an important problem? If the aims
of the application are achieved, how will scientific knowledge be advanced?
What will be the effect of these studies on the concepts or methods that drive
this field?
2. Approach. Are the conceptual framework, design, methods, and analyses
adequately developed, well-integrated, and appropriate to the aims of the
project? Does the applicant acknowledge potential problem areas and consider
alternative tactics?
3. Innovation. Does the project employ novel concepts, approaches or method?
Are the aims original and innovative? Does the project challenge existing
paradigms or develop new methodologies or technologies?
4. Investigator. Is the investigator appropriately trained and well suited
to carry out this work? Is the work proposed appropriate to the experience
level of the principal investigator and other researchers (if any)?
5. Environment. Does the scientific environment in which the work will be
done contribute to the probability of success? Do the proposed experiments
take advantage of unique features of the scientific environment or employ
useful collaborative arrangements? Is there evidence of institutional support?
The initial review group will also examine: the appropriateness of proposed
project budget and duration; the adequacy of plans to include both genders,
minorities and their subgroups, and children as appropriate for the scientific
goals of the research and plans for the recruitment and retention of subjects;
the provisions for the protection of human and animal subjects; and the safety
of the research environment.
AWARD CRITERIA
Applications will compete for available funds with all other approved
applications. The following will be considered in making funding decisions:
Quality of the proposed project as determined by peer review, availability of
funds, and program priority.
INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS
It is the policy of the NIH that women and members of minority groups and
their subpopulations must be included in all NIH supported biomedical and
behavioral research projects involving human subjects, unless a clear and
compelling rationale and justification is provided that inclusion is
inappropriate with respect to the health of the subjects or the purpose of the
research. This policy results from the NIH Revitalization Act of 1993
(Section 492B of Public Law 103-43).
All investigators proposing research involving human subjects should read the
updated "NIH Guidelines for Inclusion of Women and Minorities as Subjects in
Clinical Research," published in the NIH Guide for Grants and Contracts on
August 2, 2000, available on the Internet at:
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-048.html; a complete
copy of the updated Guidelines are available at
http://grants.nih.gov/grants/funding/women_min/guidelines_update.htm The
revisions relate to NIH defined Phase III clinical trials and require: a) all
applications or proposals and/or protocols to provide a description of plans
to conduct analyses, as appropriate, to address differences by sex/gender
and/or racial/ethnic groups, including subgroups if applicable; and b) all
investigators to report accrual, and to conduct and report analyses, as
appropriate, by sex/gender and/or racial/ethnic group differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS.
It is the policy of NIH that children (i.e., individuals under the age of 21)
must be included in all human subjects research, conducted or supported by the
NIH, unless there are clear and compelling reasons not to include them. This
policy applies to all initial (Type 1) applications submitted for receipt
dates after October 1, 1998.
All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines on the Inclusion of Children as Participants in
Research Involving Human Subjects" that was published in the NIH Guide for
Grants and Contracts, March 6, 1998, and is available at the following URL
address: http://grants.nih.gov/grants/guide/notice-files/not98-024.html.
Investigators also may obtain copies of these policies from the program staff
listed under INQUIRIES. Program staff may also provide additional relevant
information concerning the policy.
URLS IN NIH GRANT APPLICATIONS OR APPENDICES
All applications and proposals for NIH funding must be self-contained within
specified page limitations. Unless otherwise specified in an NIH
solicitation, internet addresses (URLs) should not be used to provide
information necessary to the review because reviewers are under no obligation
to view the Internet sites. Reviewers are cautioned that their anonymity may
be compromised when they directly access an Internet site.
HEALTHY PEOPLE 2010
The Public Health Service (PHS) is committed to achieving the health promotion
and disease prevention objectives of "Healthy People 2010," a PHS led national
activity for setting priority areas. This PA, Correlative Studies Using
Specimens from Mulit-institutional Prevention and Treatment Trials, is related
to priority area of cancer. Potential applicants may obtain a copy of
"Healthy People 2010" at http://www.health.gov/healthypeople/.
AUTHORITY AND REGULATIONS
This program is described in the Catalog of Federal Domestic Assistance No.
93.395. Awards are made under authorization of Sections 301 and 405 of the
Public Health Service Act as amended (42 USC 241 and 284) and administered
under NIH grants policies and Federal Regulations 42 CFR 52 and 45 CFR Parts
74 and 92. This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency review.
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and promote the non-use of all tobacco products. In addition, Public
Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain
facilities (or in some cases, any portion of a facility) in which regular or
routine education, library, day care, health care, or early childhood
development services are provided to children. This is consistent with the PHS
mission to protect and advance the physical and mental health of the American
people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||